Search clinical trials for: protein substitute

Total 37852 results

Fudan University

Recruiting

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Advanced Breast Cancer | HR+/HER2- Breast Cancer

China
Ruijin Hospital

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Diffuse Large B-Cell Lymphoma
Opna Bio LLC

Not yet recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Metastatic Breast Cancer
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Obesity

United States
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
St. Jude Children's Research Hospital
AbbVie

Not yet recruiting

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

T-cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States
Peking Union Medical College Hospital
Peking University; Shanghai Huilun Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS (STAR)

Acute Respiratory Distress Syndrome

China
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
First Affiliated Hospital of Zhejiang University

Recruiting

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

ETP-ALL

China
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Adriana Rossi

Not yet recruiting

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Li Huiping

Not yet recruiting

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Advanced Breast Cancer
National University Hospital, Singapore

Recruiting

Ma-Spore ALL 2020 Study

B Lymphoblastic Leukemia

Malaysia, Singapore
Beijing Chao Yang Hospital
Beijing Boren Hospital; Beijing Chuiyangliu Hospital

Not yet recruiting

Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

M-protein Related Cardiac Disease
metaX Institut fuer Diatetik GmbH
Great Ormond Street Hospital for Children NHS Foundation Trust; Birmingham...

Not yet recruiting

Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies (ZeroMinisMR)

Alkaptonuria | Homocystine; Metabolic Disorder | Tyrosinemia, Type I | Tyrosinemia, Type II | Tyrosinemia, Type III | MSUD (Maple Syrup Urine Disease)
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Type2 Diabetes Mellitus

China
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Type 2 Diabetes Mellitus

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma
Oncotherapeutics

Not yet recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
State University of New York at Buffalo

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Carcinoma, Renal Cell
University of Heidelberg Medical Center
Bristol-Myers Squibb; Sanofi; Wuerzburg University Hospital; KKS Netzwerk

Recruiting

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Germany
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
Assiut University

Not yet recruiting

Instillation of Gentamicin and Dexamethasone in Bronchiectasis Compared to Conventional Treatment

Bronchiectasis With Acute Exacerbation
Mayo Clinic

Not yet recruiting

Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery

Skin Cancer | Skin Cancer Face | Malignant Cutaneous Adnexal Neoplasm

United States
Oncotherapeutics
Incyte Corporation

Not yet recruiting

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Multiple Myeloma
University of Chicago

Not yet recruiting

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Lymphoblastic Lymphoma | Acute Leukemia | Lymphoblastic Leukemia

United States
Elvira Umyarova
Sanofi

Recruiting

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Quince Therapeutics S.p.A.
Biotrial

Not yet recruiting

To Evaluate the Effects of EryDex in Patients With A-T (NEAT)

Ataxia Telangiectasia

Belgium, United States, Denmark, Germany, Italy, Norway, Poland, Spain, United Kingdom
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
PETHEMA Foundation

Not yet recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL (LALPh2022)

Lymphoblastic Leukemia | Adult ALL | Philadelphia-Positive ALL
Zhejiang University

Not yet recruiting

Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica (ITTGPMR)

Polymyalgia Rheumatica
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Relapsed or Refractory Multiple Myeloma

Taiwan
AbbVie

Recruiting

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, Taiwan
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

United States, Japan, Spain, Canada, Finland, Argentina, Norway
Centre Hospitalier Universitaire de Nīmes
Institut du Cancer de Montpellier - Val d'Aurelle

Not yet recruiting

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer (EPIcol)

Cancer of Cervix | Apoptosis
Peking Union Medical College
Peking University Hospital of Stomatology

Recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Precision Therapy | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma | Neoadjuvant or Conversion Therapy

China
Sanofi

Recruiting

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (ROCKnrol-1)

Chronic Graft Versus Host Disease

Australia, Argentina, Belgium, Spain, Sweden, Czechia, United Kingdom, United States, Italy, Germany, Canada, Israel, Denmark, Brazil, Turkey
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Augusta University
Janssen Scientific Affairs, LLC

Not yet recruiting

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Multiple Myeloma | Renal Failure

United States
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
Peng Zhang

Recruiting

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis (TEN)

Toxic Epidermal Necrolysis

China

3

Subscribe